JAK2 and Alzheimer disease: After 9 months of treatment, neutralization of Aβ reduced fasting blood glucose level (p < 0.001), improved insulin sensitivity (p < 0.05), and inhibited hepatic JAK2/STAT3/SOCS1 signaling (p < 0.05) in APP/PS1 AD model rats.